SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as market participants react to the escalating geopolitical tensions involving the U.S. and Iran, specifically centered on threats to the Strait of Hormuz. The community is sharply divided, with intense debate ongoing regarding the potential for an immediate resolution versus a prolonged conflict, while traders closely monitor oil prices and institutional hedging as indicators for the next market trend.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant volatility driven by a combination of geopolitical tensions, including concerns over Middle Eastern supply chains, and legal headwinds stemming from a jury verdict regarding past investor disclosures. Market participants are actively debating the company's long-term outlook, with discussion focused on the potential impact of high-cost 'Terafab' infrastructure plans on future profitability versus the long-term potential of its AI and robotics initiatives.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members express significant apprehension regarding the escalating geopolitical conflict in the Middle East and its potential impact on the broader market. Discussion is dominated by heated debates over the administration's foreign policy, concerns about rising energy costs, and widespread skepticism regarding the company's long-term stability amidst ongoing market volatility.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is surging as a primary beneficiary of the ongoing Middle East energy crisis, with the community closely tracking the potential for a massive short squeeze driven by extremely low float and record-breaking volume. Investors are hyper-focused on the company's natural gas assets in Italy as a critical energy security play, while the message boards are buzzing with intense debate over potential warrant exercises and whether the stock's momentum can mirror past sector runners.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as geopolitical volatility in the Middle East intensifies following a high-stakes 48-hour ultimatum by the U.S. regarding the Strait of Hormuz. The community is actively debating whether energy prices will continue to spike due to potential supply infrastructure disruptions or if the market has already reached a short-term peak as diplomatic chatter and military deployment news create deep uncertainty.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Markets are exhibiting heightened volatility as traders weigh a time-sensitive ultimatum issued to Iran regarding the Strait of Hormuz against fears of a deepening global energy crisis. The community is actively debating the potential for a sharp corrective pullback in tech-heavy indices while speculating on whether ongoing diplomatic maneuvers will result in a rapid de-escalation or a sustained economic downturn.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The Technology Select Sector SPDR Fund (XLK) is currently navigating significant volatility as market participants monitor high-beta leadership from companies like Nvidia and Apple while weighing broader economic uncertainty and sector rotation. The community is intensely focused on technical indicators, such as potential head-and-shoulders patterns and key support levels, as traders debate whether current tech valuation levels represent a sustainable growth trajectory or an overextended bubble nearing a correction.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense volatility and downward pressure as investors abandon the metal amid a strengthening dollar and surging bond yields. The community is sharply divided, with many debating whether this is a structural failure of gold's safe-haven narrative or a massive liquidity flush offering a generational buying opportunity.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors weigh strong China smartphone sales against broader market concerns over stagflation, geopolitical volatility in the Middle East, and the potential impact of interest rate uncertainty on tech valuations. While some in the community highlight the firm's resilient hardware ecosystem and AI-driven growth potential, many are actively debating the stock's recent underperformance and technical breakdown, with traders focused on critical support levels near the 200-day moving average.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is currently trending as investors rotate capital into financials and industrials while monitoring interest rate policy and sector-wide bank earnings. Community discussions focus on the fund's resilience amidst broader market volatility, with many traders closely watching key technical support levels and institutional rotation patterns as potential indicators for the next market move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BURLINGTON, Ontario--(BUSINESS WIRE)-- Anaergia Inc. (“Anaergia” or the "Company") (TSX: ANRG) (OTCQX: ANRGF) will hold a conference call on Thursday, March 26, 2026, at 10:00 a.m. ET, during which Chief Executive Officer Assaf Onn, Chief Financial Officer Greg Wolf, and Chief Operating Officer Dr. Yaniv Scherson will discuss the Company’s financial results for the fourth quarter and fiscal year ended December 31, 2025. The Company plans to release its financial results after the market closes on Wednesday, March 25, 2026.Shareholders and other interested parties may register for the live, listen-only webcast, here: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F838906175&amp;esheet=54457759&amp;newsitemid=20260320700916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F838906175&amp;index=1&amp;md5=4b4a1fc45e2e44e136940a33a31ddf26">https://events.q4inc.com/attendee/838906175</a>. An accompanying slide presentation will be posted to the Investor Relations section of the Company’s website shortly before the call.A replay of the webcast will be available on the Events section of the Anaergia website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anaergia.com&amp;esheet=54457759&amp;newsitemid=20260320700916&amp;lan=en-US&amp;anchor=www.anaergia.com&amp;index=2&amp;md5=a20d30615e7365816c8913740a528b9e">www.anaergia.com</a>, where it will remain available for approximately one year after the conference call.About AnaergiaAnaergia is a pioneering technology company in the RNG sector, with hundreds of patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. It is committed to addressing a significant source of greenhouse gas (“GHG”) emissions through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today’s critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by us, by third parties, or through joint ventures. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anaergia.com&amp;esheet=54457759&amp;newsitemid=20260320700916&amp;lan=en-US&amp;anchor=www.anaergia.com&amp;index=3&amp;md5=fd99f4e3431fd84a1a562b60521bf75e">www.anaergia.com</a>For media and/or investor relations please contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:IR@Anaergia.com">IR@Anaergia.com</a>Source: Anaergia Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Anaergia Inc. Schedules Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call

Anaergia hosts a Q4/FY 2025 earnings call March 26, 2026, at 10 a.m. ET following results on March 25.

Others

NEW YORK, March 20, 2026 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4646130-1&amp;h=3378504652&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>, a provider of ETFs designed for sophisticated investors and professional traders, announced that it has surpassed $3 billion in assets under management (AUM) in under two years since its launch. Tradr attributes this success to its formula – identifying unmet market demand from traders and active investors, and then working to satisfy that demand with timely, precision trading products.Since its launch in May 2024, Tradr now has 8 ETFs with more than $100m in AUM, including:<ul><li>Tradr 2X Long SNDX Daily ETF (SNXX) - $786m &nbsp;</li><li>Tradr 2X Long LITE Daily ETF (LITX) - $417m &nbsp;</li><li>Tradr 2X Long ASTS Daily ETF (ASTX) - $282m &nbsp;</li><li>Tradr 2X Short TSLA Daily ETF (TSLQ) - $182m &nbsp;</li><li>Tradr 2X Long NBIS Daily ETF (NEBX) - $143m &nbsp;</li><li>Tradr 2X Long APP Daily ETF (APPX) - $136m &nbsp;</li><li>Tradr 2X Long CRWV Daily ETF (CWVX) - $111m &nbsp;</li><li>Tradr 2X Long Innovation 100 Monthly ETF (MQQQ) - $109m</li></ul>"Crossing $3 billion in AUM marks another significant step in Tradr's growth trajectory," said Russell Tencer, President of Tradr ETFs. "Investors are increasingly turning to our precision-built leveraged ETFs, and we believe this momentum positions us as a clear leader in the next phase of the category's evolution."Tradr now offers 67 ETFs and, as a pioneer of leveraged ETFs, has rapidly gained traction with active traders, institutions and retail investors alike. It continues to expand its product line by targeting stocks that traders follow, including high-volume names with elevated volatility, recent IPOs, and companies in innovative sectors such as AI storage and infrastructure, high-bandwidth memory, optical networking, satellite constellations and broadband, and autonomous transportation.For detailed information on Tradr ETFs and the significant risks involved with inverse and leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4646130-1&amp;h=2073319261&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4646130-1&amp;h=3378504652&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a> are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4646130-1&amp;h=2073319261&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000875SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr ETFs Reaches $3 Billion AUM Milestone in Under Two Years

Reflects strong enthusiasm for the Tradr family of single-stock and calendar reset leveraged ETFs

VICTORVILLE, California &amp; BURLINGTON, Ontario--(BUSINESS WIRE)-- Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG; OTCQX: ANRGF) reports that the California Public Utilities Commission (“CPUC”) has conditionally approved a long-term biomethane procurement contract between Anaergia’s SoCal Biomethane LLC (“SoCal Biomethane”) facility, Anew Climate LLC, and Southwest Gas. The project will be the first to supply RNG under California’s Senate Bill (SB) 1440 Biomethane Procurement Program.This positions Anaergia at the forefront of California’s decarbonization strategy and effort to scale renewable natural gas (“RNG”) produced from organic waste. California SB 1383 targeted a dramatic reduction in organic waste, and SB 1440 now establishes a requirement on California’s Investor-Owned Utilities (IOU) to procure RNG derived from landfill-diverted organic waste at a scale equivalent to approximately 55 facilities the size of SoCal Biomethane by 2035.Anaergia’s SoCal Biomethane facility is located at the Victor Valley Wastewater Reclamation Authority (“VVWRA”) and co-digests organic waste and municipal wastewater to produce biogas that is upgraded to RNG and injected into the gas pipeline for distribution. The facility can accept up to 104,000 tons of diverted organic waste annually and has the potential to reduce emissions by up to 31,710 MTCO2e per year, equivalent to emissions from approximately 7,400 gasoline-powered passenger vehicles annually. The project also provides local economic benefits to Victorville, Apple Valley, and Hesperia by employing local staff.“Anaergia is proud that our facility will be the first to supply SB 1440-qualified RNG in California,” said Assaf Onn, Anaergia’s Chief Executive Officer. “This milestone demonstrates how existing wastewater infrastructure can be leveraged to rapidly scale RNG supply from organic waste as mandated by California laws SB 1383 and SB 1440.”“Long‑term offtake agreements from natural gas utilities support state climate goals, and we appreciate the CPUC’s leadership in advancing projects that deliver real, local emissions reductions,” said Ryan Childress, Managing Director of Low Carbon Fuels at Anew Climate. “This is a meaningful step toward scaling renewable, baseload energy.”Darron Poulsen, General Manager of the Victor Valley Wastewater Reclamation Authority, added, “VVWRA is proud to be part of California’s first project delivering RNG under Senate Bill 1440. Wastewater facilities like ours are uniquely positioned to turn organic waste into clean, renewable energy, and this partnership with Anaergia shows just how impactful that collaboration can be. SB 1440 provides a critical framework that accelerates the development of projects that reduce methane emissions, support grid reliability, and strengthen local communities. We strongly support this legislation and look forward to continuing our work with Anaergia to advance sustainable, cost‑effective solutions for the Victor Valley and the State of California.”Sam Wade, VP of Public Policy for RNG COALITION, said “The SoCal Biomethane facility is a great example from which California can build. Our state can and should retrofit other existing wastewater plants in the state to process organic waste, reduce greenhouse gases, and generate renewable natural gas, a low-carbon alternative to fossil fuels consumed across society. We applaud all parties involved, including multiple Coalition members, for their leadership on this important breakthrough project."About Anew ClimateAnew Climate, LLC, is a global leader of diverse climate solutions built on the principles of transparency and accountability. With an expansive portfolio of low and negative carbon fuels, Anew Climate delivers tailored solutions that reduce emissions and accelerate sustainability goals across diverse market segments. Anew is majority owned by TPG Rise, TPG’s global impact investing platform. The company has offices in the U.S., Canada, Germany, Hungary, and Spain with an environmental commodities portfolio that extends across five continents.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anewclimate.com&amp;esheet=54456711&amp;newsitemid=20260320957200&amp;lan=en-US&amp;anchor=www.anewclimate.com&amp;index=1&amp;md5=d18651b4b56245f3458b706549cbe804">www.anewclimate.com</a>About Victor Valley Wastewater Reclamation AuthorityVVWRA serves a 279 square mile area that includes Apple Valley, Hesperia, Victorville, Spring Valley Lake, and Oro Grande. VVWRA treats about 12 million gallons of wastewater per day. Wastewater that comes to the VVWRA plant goes through an extensive cleaning and disinfection process before being returned to the Mojave River as recycled water through direct discharge to the river or through percolation ponds located on VVWRA property.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vvwraca.gov&amp;esheet=54456711&amp;newsitemid=20260320957200&amp;lan=en-US&amp;anchor=www.vvwraca.gov&amp;index=2&amp;md5=8b7f7dca5978bc1dd80d337fe6b330e8">www.vvwraca.gov</a>About RNG COALITIONRNG COALITION is the non-profit association providing industry leadership, education and advocacy for RNG development as a sustainable source for clean fuel, heat, power, products and services.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rngcoalition.com&amp;esheet=54456711&amp;newsitemid=20260320957200&amp;lan=en-US&amp;anchor=www.rngcoalition.com&amp;index=3&amp;md5=661147af6379c096f30f68747c11a2fd">www.rngcoalition.com</a>About AnaergiaAnaergia is a pioneering technology company in the RNG sector, with hundreds of patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. It is committed to addressing a significant source of greenhouse gas (“GHG”) emissions through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today’s critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by us, by third parties, or through joint ventures. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anaergia.com&amp;esheet=54456711&amp;newsitemid=20260320957200&amp;lan=en-US&amp;anchor=www.anaergia.com&amp;index=4&amp;md5=f8c48991df4aeef81c22dc7c68b234a5">www.anaergia.com</a>Forward-Looking StatementsThis news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia’s current expectations regarding future events. Forward-looking information is based on a number of assumptions, including, but not limited to, counterparty contractual performance and the capability of the Company’s technology and performance with respect to the project objectives. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the Company’s annual information form for the fiscal year ended December 31, 2024, and under “Risks and Uncertainties” in the Company’s most recent management’s discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia’s operations or financial results are included in Anaergia’s reports on file with Canadian regulatory authorities.For media or investor relations please contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:IR@Anaergia.com">IR@Anaergia.com</a>Source: Anaergia Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

California Public Utilities Commission Conditionally Approves RNG Procurement Contract from Anaergia’s SoCal Biomethane Facility

Anaergia’s Facility To Be The First Project To Supply RNG Under Senate Bill 1440 - California’s Biomethane Procurement Program

Vancouver, British Columbia, (March 19, 2026) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its previously disclosed Interceptor P-1 single-use, one-way autonomous drone being developed by its ZenaDrone subsidiary, is being designed to have a target selling price of under $5,000 USD. The company previously disclosed it has initiated development of a prototype version for the small, one-way interceptor drone designed to stop hostile drones by physically intercepting them in-flight. The Interceptor P-1 is being built as an autonomous and expendable vertical takeoff and landing (VTOL)-design drone that can be added to the company’s counter-UAS (Unmanned Aircraft System) defense system offering dramatically lower costs than traditional air munitions.“We are engineering the Interceptor P-1 with a clear goal: maximize performance while minimizing cost. The result is a smarter, more accessible solution for modern aerial operations targeted to sell for less than $5,000 per drone for the new world of asymmetric warfare,” said Shaun Passley, PhD, ZenaTech CEO. “The Interceptor P-1 is a critical piece of ZenaDrone’s integrated defense ecosystem, designed to work seamlessly with our interceptor platforms and marine launch station, and enabling a coordinated drone-on-drone solution that delivers a unified, cost-effective aerial defense capability for U.S. Defense and allied forces.”The Interceptor P-1 is designed to address a critical asymmetry in modern warfare. Adversaries routinely deploy low-cost commercial and military drones at scale, while conventional intercept solutions — including surface-to-air missiles and laser systems — carry costs that are orders of magnitude higher than the threats they defeat. The Interceptor P-1 prototype is being purpose-built to reverse this equation.With versatile launch options planned, including ground, vehicle, and maritime deployment via the company’s IQ Glider maritime drone platform, the Interceptor P-1 is being built to respond rapidly across multiple environments. By offering scalable interception capabilities, it is designed to help defense forces protect critical infrastructure, manage enemy drone swarms, and complement existing air defense systems as a strategic addition to the ZenaDrone counter-UAS platform.The company is targeting an initial prototype completion in the upcoming months and will provide further updates on product development, regulatory milestones, and defense and government agency engagement and pilots as progress continues.The global counter-UAS market is growing at over 25% per year, projected to exceed $10 billion by 2030 according to<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketsandmarkets.com/Market-Reports/counter-cuas-systems-market-4197284.html"> Markets and Markets</a>, driven by intensifying drone warfare in multiple active theaters and the proliferation of commercially available drones repurposed for battlefield use. ZenaTech management believes the company is positioning the Interceptor P-1 for future procurement opportunities that includes allied governments, NATO partners, and Gulf Cooperation Council (GCC) defense customers.About ZenaTech <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.droneasaservice.com/?__hstc=67789070.8f62dd1a214c40d92bb3086a7f3015fc.1771008991807.1773851255689.1773925552393.14&amp;__hssc=67789070.2.1773925552393&amp;__hsfp=8eae9a2a09c989a8d1ac9c25aacbf4b0"> Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.About ZenaDrone <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.zenadrone.com/">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications.Currently, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/zenadrone-iq-square/"> IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/iq-quad-drone/"> IQ Quad</a> is for land surveys.Contacts for more information: Company, Investors, and Media:Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Safe Harbor This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.&nbsp; Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MCJEA-jZovtm7y6ff50FGFHBj5GRIx2tUeuiQgna0unRNYqf61tDuQbFv1jMul2mqArzrhiCgrT7c0s2UFe4WA==">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech’s ZenaDrone Interceptor P-1, Single-Use Autonomous Interceptor Drone, Targeted to Sell for Under $5,000 USD

Part of ZenaDrone’s Counter-UAS defense system being built for modern asymmetric warfare for U.S. Defense and allied forces

TREVIGLIO, Italy &amp; BURLINGTON, Ontario--(<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/">BUSINESS WIRE</a>)--An Italian subsidiary of Anaergia Inc. (“Anaergia,” the “Company,” “we,” or “our”) (TSX: ANRG) (OTCQX: ANRGF), Anaergia S.r.l., signed amendments to three previously announced contracts with an entity owned by QGM S.à.r.l. (“QGM”), relating to the development of three state-of-the-art biomethane production facilities in Ostellato, Copparo, and Derovere, in northern Italy.As a result of these amendments, the scope of Anaergia S.r.l.’s activities across the three projects has expanded, increasing the Company’s total contracted value from approximately C$68 million to approximately C$85 million, representing an increase of C$17 million.The three QGM projects, previously announced on March 31, 2025, and August 6, 2025, will leverage Anaergia’s advanced anaerobic digestion technologies to convert a range of agricultural residues into renewable biomethane. The facilities are expected to contribute meaningfully to Italy’s decarbonization objectives by supporting the production and injection of renewable gas into the national pipeline network.“The expansion of our scope across these three projects demonstrates Anaergia’s focus on building long-term, repeat partnerships while delivering scalable biomethane solutions,” said Assaf Onn, Chief Executive Officer of Anaergia.About AnaergiaAnaergia is a pioneering technology company in the RNG sector, with hundreds of patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. It is committed to addressing a significant source of greenhouse gas (GHG) emissions through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today’s critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by us, by third parties, or through joint ventures. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions.For further information please see: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anaergia.com&amp;esheet=54451681&amp;newsitemid=20260317031547&amp;lan=en-US&amp;anchor=www.anaergia.com&amp;index=1&amp;md5=06783c0f70ad3db3dc3d17aa2c079b3f">www.anaergia.com</a>Forward-Looking StatementsThis news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia’s current expectations regarding future events, including but not limited to, counterparty contractual performance, the capability of the Company’s technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the development, timing and funding of the facilities, the capability of the Company’s technology and performance with respect to the project objectives, the expected additional revenue from the expanded scope and the specific projects under the agreement, and the sufficient sourcing of agricultural waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the Company’s annual information form for the fiscal year ended December 31, 2024, and under “Risks and Uncertainties” in the Company’s most recent management’s discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia’s operations or financial results are included in Anaergia’s reports on file with Canadian regulatory authorities.<h2 class="block font-figtree whitespace-pre-line [&amp;_a]:underline [&amp;_a]:decoration-tertiaryBright [&amp;_a:hover]:no-underline text-primary [&amp;_a]:text-primary text-2xl leading-[1.27em] lg:leading-[1.45em] font-semibold ui-kit-press-release-contacts__headline">Contacts</h2>For media and/or investor relations please contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:IR@Anaergia.com">IR@Anaergia.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Anaergia S.r.l. Expands Scope at Three Biomethane Facilities Being Built for QGM S.á.r.l. in Italy, Increasing Contracts by C$17 Million

Total Expected Revenues from the Three Projects Increase from C$68 Million to C$85 Million

Vancouver, British Columbia, (March 17, 2026) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions,&nbsp; announces that its ZenaDrone subsidiary has initiated development of a prototype for a small, one-way interceptor drone designed to stop hostile drones by physically intercepting them in flight. The prototype, called Interceptor-P1, is an autonomous and expendable vertical takeoff and landing (VTOL)-design drone that can be added to the company’s counter-UAS (Unmanned Aircraft System) defense system offering dramatically lower costs than traditional air munitions.&nbsp;The drone addresses a critical asymmetry in modern warfare. Adversaries routinely deploy low-cost commercial and military drones at scale, while conventional intercept solutions, including surface-to-air missiles and laser systems, carry costs that are orders of magnitude higher than the threats they defeat. The Interceptor-P1 prototype is being purpose-built to reverse this equation.“The drone threat on modern battlefields is accelerating faster than legacy defense budgets can absorb. Our Interceptor-P1 is being developed to give military and security forces an affordable, scalable answer by creating an interceptor and anti-drone system for a new world of asymmetric warfare,” said Shaun Passley, PhD, ZenaTech CEO. “Our strategy is to offer defense customers a full-spectrum of counter-drone solutions based on persistent maritime patrol with the ZenaDrone 2000 and IQ Glider launch station.&nbsp; Our emerging technologies are also forming a comprehensive, layered, counter-UAS ecosystem for land, sea, and littoral environments with the expendable point-intercept capabilities of the Interceptor-P1. This is exactly the kind of integrated, cost-effective capability that modern defense procurement demands.”With versatile launch options planned, including ground, vehicle, and maritime deployment via the company’s IQ Glider, maritime drone platform, the Interceptor P-1 is being built to respond rapidly across multiple environments. By offering scalable interception capabilities, it is designed to help defense forces protect critical infrastructure, manage enemy drone swarms, and complement existing air defense systems as a strategic addition to ZenaDrone counter-UAS platform.The company is targeting an initial prototype completion in the upcoming months and will provide further updates on product development, regulatory milestones, and defense and government agency engagement and pilots as progress continues.The global counter-UAS market is growing at over 25% per year, projected to exceed $10 billion by 2030 according to <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketsandmarkets.com/Market-Reports/counter-cuas-systems-market-4197284.html">Markets and Markets</a>, driven by intensifying drone warfare in multiple active theaters and the proliferation of commercially available drones repurposed for battlefield use. ZenaTech management believes the company is positioning the Intercept P-1 for future procurement contract opportunities with allied governments, NATO partners, and Gulf Cooperation Council (GCC) defense customers. About ZenaTech <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.droneasaservice.com/">Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions. About ZenaDrone <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.zenadrone.com/">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications.&nbsp;Currently, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/">ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/">IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/zenadrone-iq-square/">IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/iq-quad-drone/">IQ Quad</a> is for land surveys.&nbsp;Contacts for more information: Company, Investors, and Media: &nbsp;Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a> &nbsp;Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Safe Harbor This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. &nbsp;Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity;&nbsp;ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano;&nbsp;ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing;&nbsp;ZenaTech’s intention to grow the business and its operations and execution risk;&nbsp;expectations with respect to future operations and costs;&nbsp;the volatility of stock prices and market conditions in the industries in which ZenaTech operates;&nbsp;political, economic, environmental, tax, security, and other risks associated with operating in emerging markets;&nbsp;regulatory risks;&nbsp;unfavorable publicity or consumer perception;&nbsp;difficulty in forecasting industry trends;&nbsp;the ability to hire key personnel;&nbsp;the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months;&nbsp;ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments;&nbsp;investment capital and market share; the ability to complete any contemplated acquisitions;&nbsp;changes in the target markets;&nbsp;market uncertainty;&nbsp;ability to access additional capital, including through the listing of its securities in various jurisdictions;&nbsp;management of growth (plans and timing for expansion);&nbsp;patent infringement;&nbsp;litigation;&nbsp;applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MCJEA-jZovtm7y6ff50FGFHBj5GRIx2tUeuiQgna0unRNYqf61tDuQbFv1jMul2mqArzrhiCgrT7c0s2UFe4WA==">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech Develops Low-Cost, Single-Use Autonomous Interceptor Drone for ZenaDrone’s Counter-UAS System for US Defense, Middle East, and Ukraine Use

Designed to defeat enemy drones at a fraction of the cost of conventional air defense systems

VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its ZenaDrone subsidiary has filed a provisional patent application for its maritime drone defense system combining the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=y50yXFl2sLc4oHQghSGmAT6L_oGUnJgyeh8dPM7InBy0S5xCwoXSj7XxR-TFLlBMBh_rebzHbCaYlupXZCHVQu_mL_HtsFFr-OuiodhfMRyz5DE07RrY3G279L7Xz8BWS7lq91TF0jV8m0iXyiZghWV5BOPVtO8npXEKqDx0lwtvq1EILs1UDmYIxtzavzwi9CDc0vV1IDc1dBPihB4s331Hpa6lYgRCHSOynvgB9UdTnvMXgTdG_-cMlbqTn6A7jZfL2Qjm2ZntiaZXi8D6DZLELP2l1ermzGlzH4khqaaD_22qQMTLTGxrGM8jBuZG">ZenaDrone 2000</a> maritime interceptor drone and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=u02F4HHotW3DXmZr8TL7wB-s0JRhS8xTJj5I45MIdwGZ_kygn_iux-_dCyNEMA5-G-CQ0XQw1QV7m_iTH7KN7nirpLFrYUqZxyzedEUiOkIBYZ5VJUy8jSYOK6W_vnyJcH6lMwSlWRMI8sR38k5LLhjR6QwIptDDfB65nd5bGg3-kYbOXUpGFzCTI_TiZcdVZi917xLdLc0KPDtwyCiKysSLkE2FC0lo1Ag8IzKkIDvy9u4eeVwg6bSm7ZaPF911FyR5wheU0fbXWVktY9gpAGXateoeIsOvYp3e0Zm4SKk=">IQ Glider</a> autonomous marine launch and refueling station. The patent application covers the company’s counter-UAS system architecture, designed to enable persistent, ship-based drone interception capable of autonomously detecting, engaging, and intercepting multiple incoming unmanned aerial threats. The provisional patent was filed with the United States Patent and Trademark Office and represents the first step in building a defensible intellectual property portfolio for the company’s maritime defense system. “Protecting our intellectual property is a critical component of our long-term strategy and continued success of the company,” said Shaun Passley, PhD, ZenaTech CEO. “This patent filing will help create a broad portfolio of intellectual property around this program and potential future programs. As drone warfare continues to evolve, protecting the core technologies behind our next-generation defense systems is essential. With a deliberate patent filing program, our goal is to secure a defensible position around technologies we believe will be central to autonomous maritime defense. These are built for the new era of asymmetric warfare, where the economies of multimillion-dollar missiles pitted against a swarm of cheap drones are no longer viable.”The patent application covers the ZenaDrone 2000 interceptor drone as well as the integrated system architecture that enables the IQ Glider marine station, which is designed to autonomously launch and refuel multiple ZenaDrone 2000 interceptor drones from a maritime vessel. Achieving patent-pending status is the start of creating a defensible IP moat around the combined ZenaDrone 2000 and IQ Glider system.Operating ZenaDrone 2000 interceptor drones in a continuous relay launching from the IQ Glider marine station, the system is designed to provide constant aerial interception coverage capable of detecting, tracking, and intercepting multiple incoming drones or drone swarm threats. Key elements of the system are expected to include autonomous docking and refueling sequencing, multi-drone relay operations enabling uninterrupted coverage, and AI-driven navigation and threat engagement capabilities designed to operate in complex or GPS-denied environments.Both the IQ Glider and the ZenaDrone 2000 interceptor drone are currently in active development. The ZenaDrone 2000 gas-powered prototype is at the design and development stage, with testing expected before the end of the year. The IQ Glider is being developed in parallel as the dedicated launch and refueling infrastructure for ZenaDrone 2000 fleet operations. ZenaTech will provide updates on combined system development milestones, prototype testing timelines, patent updates, and defense customer engagement as they are achieved.About ZenaTech<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=JvO9q088X24wrYnVpvwV1z3-nA4wfGIeDnVyALSrDJft9f2iHVoRyJWvqd4GSAT3QSKM_tqmHnYwyfEmq_93Ig==">ZenaTech</a> (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Of4E-skrokFKYRsg4IyCAoskXDTboTZ5cVfFjz9ysa0BkyqQ2l7nf_mEfVqBjGZsL18IOqZPyHQUeFbJptym4qCv_ORdOGvJHkSTusLnASk=">Drone as a Service</a> (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.About ZenaDrone&nbsp;&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=y50yXFl2sLc4oHQghSGmARQnR0_kp0gg2mEC0KS140LLKD_7qHMha1DDQtqx4DXMd2KJwTUi2YBKsFtTLx-GVQ==">ZenaDrone</a>, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications.Currently, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=y50yXFl2sLc4oHQghSGmAZz1A4x91WnI7yJltZG-JmfZodVuOMs4WhUBY_a3Ok7V45pPxeSbpinFdSQE7BZ3JqR4NNiKy6_7lnaKFowwE6C_VhdCPkDp97ry99GZL23Y">ZenaDrone 1000</a> drone is used for crop management applications and critical field cargo applications in the defense sector, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=YjzZnaIBsjO1_pmBACyRLmn3qxt1u-FaESrmrRCS4Lb_v4DU8J_hmLgVxOBI9_P9gjD0ks-HnzlaeaJdr349iqQ7WTaG_kWqPwr1qtFbQc2hVMU3IGyqHKRzNN54b6ek">IQ Nano</a> indoor drone is used for inventory management and security in the warehouse and logistics sectors, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=7hkknJTOfnk7XIRLkLDCgjNwhPRscqCfqKApUhnAHIvMeFLow8DcN8xFxjzmZiEDEVz9NBlyoNMLeJOa4I8Pvwy8O0cohFfaDF2iKQ-HZrSrqoqCnd7S82Hg6DpSfuym">IQ Square</a> is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=4qXnNUxtSAe9tvRfseLa1bquXIYfihDCQGcEJqtfyeVgeMxuK8rfF54gFQ8NCC-I7tMKOIdR256lzQUNw6d6ZFDrtKJCM4JLrW5wBXYWCSk=">IQ Quad</a> is for land surveys.Contacts for more information:Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=UPBrAX0jNZmIWTFCRio6QYeFhNVQNYjs7rqsEcvK4344ezbQKsSE9U5LcSoefqJ6D7bcGeIiLzuHMDbe8oXyglyR5zfP8jP9wlUizhl9j9M=">investors@zenatech.com</a>Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=UPBrAX0jNZmIWTFCRio6QYeFhNVQNYjs7rqsEcvK437pZPMRnYAiZsy3LdIwpQG77DdbigVeNGDuq64oGoYgNXMR7u6Q7mJlz3J3ZJW26FA=">investors@zenatech.com</a>Safe HarborThis press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. &nbsp;Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity;&nbsp;ZenaTech's ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano;&nbsp;ZenaTech's ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing;&nbsp;ZenaTech’s intention to grow the business and its operations and execution risk;&nbsp;expectations with respect to future operations and costs;&nbsp;the volatility of stock prices and market conditions in the industries in which ZenaTech operates;&nbsp;political, economic, environmental, tax, security, and other risks associated with operating in emerging markets;&nbsp;regulatory risks;&nbsp;unfavorable publicity or consumer perception;&nbsp;difficulty in forecasting industry trends;&nbsp;the ability to hire key personnel;&nbsp;the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months;&nbsp;ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments;&nbsp;investment capital and market share; the ability to complete any contemplated acquisitions;&nbsp;changes in the target markets;&nbsp;market uncertainty;&nbsp;ability to access additional capital, including through the listing of its securities in various jurisdictions;&nbsp;management of growth (plans and timing for expansion);&nbsp;patent infringement;&nbsp;litigation;&nbsp;applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=JJ-Kizzupqyo-Pk_4YkRkjU6k_lIRlmsKig5HXG9xWgLkqy5FjaWkE43IUOuZq_nC2McGB3olnW2G9qIqBTvF2zk7b3KXfG0KWHBidbfk0HW5GgD9kEraEPHH8EJybQZI8XKrTq-_cVaZbXtQMzPIYrIcjreWpPNmnmb5UHkveLlzS9aS-Uyv3lNBo7WB3I-lbiSAEMrij_BxsdExGbTNz3X1O-xqVXZPrIDu0ZEroU=">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎ Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech’s ZenaDrone Announces the Filing of a Patent for its Maritime Defense System Combining ZenaDrone 2000 Interceptor Drone and IQ Glider Autonomous Marine Station

Company secures patent-pending status to protect novel architecture for a constant, ship-based autonomous drone interception system designed to counter drone swarm threats at a fraction of the cost of missile-based countermeasures

<ul><li>HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings</li><li>ALIGN-ACS study expected to complete patient enrollment quickly</li><li>Milestone signifies key step toward future FDA indication expansion for heart attack assessment</li><li>Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia. The initiation of the ALIGN-ACS pilot study represents a significant step toward collecting the data needed to support expanding the indication of the HeartBeam System beyond arrhythmia assessment to include heart attack assessment.Heart attacks remain the leading cause of death, with more than 20 million patients in the U.S. who are at risk. Patients often delay seeking care by 3–4 hours because symptoms can be vague or subtle, driving up mortality, complications, and cost of care. While a 12-lead ECG remains the standard of care for diagnosing a heart attack, there is no reliable method for physicians to assess possible heart attacks outside of a clinical setting. HeartBeam aims to fill this gap and shorten <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.heart.org/news/acting-quickly-after-heart-attack-symptoms-start-can-be-a-heart-saver">“symptom-to-door” times</a>by enabling patients to record a clinical-grade ECG the moment symptoms begin, wherever they are. By capturing the heart’s electrical signals in 3D, from 3 non-coplanar dimensions, HeartBeam’s 3D ECG technology provides physicians with a high-fidelity, reliable way to assess possible heart attacks outside of a clinical setting.“Every minute matters during a heart attack, and early, accurate identification of a heart attack is essential to ensuring patients receive the care they need in a timely manner and improving outcomes,” said HeartBeam Scientific Advisory Board Chair C. Michael Gibson, MD, FRCP, FAHA, FSCAI, FACC, Interventional Cardiologist at Beth Israel Lahey and Professor of Medicine at Harvard Medical School. “HeartBeam’s technology has the potential to meaningfully change how quickly we evaluate patients by providing timely access to clinical-grade ECG data outside the hospital, enabling clinicians to accelerate triage decisions and intervene sooner.”The ALIGN-ACS pilot study is designed to enroll 100 patients presenting with chest pain in the emergency room (ER). Patients will be evaluated with both a standard 12-lead ECG and the HeartBeam device and both results will be compared with each patient’s final diagnosis at discharge. As the study is designed to enroll chest pain patients in the ER, enrollment is expected to progress quickly.The pilot study builds on multiple earlier <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/evidence#:~:text=Heart%20Attack%20Detection">proof of concept studies</a> demonstrating that a 3D ECG configuration similar to the HeartBeam device’s ability to detect heart attacks was similar in accuracy to a standard 12-lead ECG, including a study presented at the 2025 American Heart Association Scientific Sessions on the 3D approach. Learnings from the ALIGN-ACS pilot study will inform the design of a multicenter pivotal study that would serve as the basis of a future FDA submission.“HeartBeam was founded on the premise that since most heart attacks happen outside of a hospital, there should be a fast and easy way for patients and physicians to assess both symptoms and ECG data at home or anywhere,” said Robert Eno, Chief Executive Officer for HeartBeam. “The initiation of our pilot study for heart attack detection is a defining moment for HeartBeam as this is one of the largest clinical opportunities in cardiology. Our platform is uniquely positioned to deliver clinical-grade ECG insights at the moment symptoms occur and facilitate more timely action to close the ‘symptom-to-door’ gap.”This milestone aligns directly with HeartBeam’s key long-term growth initiatives, which also include the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam received FDA clearance for arrhythmia assessment for its 3D ECG technology in December 2024 and for its 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.MKT-109 v1&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260305231175/en/">https://www.businesswire.com/news/home/20260305231175/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a> Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 5, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study

HeartBeam starts ALIGN-ACS study to validate 3D ECG for home-based heart attack detection.

<ul><li>Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk</li><li>Combines Mount Sinai’s world-class AI and clinical expertise with HeartBeam’s groundbreaking 3D ECG signal collection technology</li><li>HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings</li><li>Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from 3 non-coplanar dimensions. The partnership marks a significant milestone in the Company’s long-term strategy to build an ecosystem around its platform and strengthen its leadership in AI-enabled cardiac monitoring.A core value driver of the collaboration is HeartBeam’s differentiated ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development. This creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings, supporting both wellness use cases and clinically relevant assessments, such as heart attack risk.The combination of HeartBeam’s continuously expanding dataset and Mount Sinai’s clinically annotated 12-lead ECG data can accelerate the training and validation of various AI models. Over time, this collaboration will result in a data engine that is expected to support the development of increasingly personalized algorithms—positioning HeartBeam to expand into new clinical indications and reimbursement pathways.“We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities,” said Robert Eno, Chief Executive Officer of HeartBeam. “By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai’s extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity.”Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership.“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems. Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional health care settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs. By combining deep learning tools with the ability to record full 3-dimensional cardiac electrical activity without cables, we can provide clinically meaningful and operationally pragmatic models at scale regardless of environment,” said Dr. Lampert, Cardiac Electrophysiologist, Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital and Director of Cardiovascular Artificial Intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai.Pairing HeartBeam’s innovative hardware and approach to cardiac waveform engineering with Mount Sinai’s advanced AI and clinical expertise creates a powerful foundation for developing tools that dynamically meet modern patient and clinician needs wherever they are.“Heart disease doesn’t only show up during a brief visit to the clinic. This collaboration gives us an opportunity to bring powerful clinical-grade heart monitoring into patients’ daily lives,” said Dr. Nadkarni. “By combining advanced AI with HeartBeam’s ability to capture full 12-lead ECG signals from home over time, we can study the heart in ways that simply haven’t been possible before—helping clinicians detect risk earlier and guide care more precisely.”“This collaboration addresses an important need by leveraging deep learning and 3-dimensional waveform data for scalable diagnostic and predictive purposes, allowing insights beyond even expert human ability,” added Dr. Reddy, who serves as the Director of Cardiac Arrhythmia Services for Mount Sinai Health System.Together, the two organizations aim to accelerate the development of high-value algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. By enabling AI models to operate on longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.About the Mount Sinai Health SystemMount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News &amp; World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News &amp; World Report® “Best Hospitals” Honor Roll for 2025-2026.For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.mountsinai.org/">https://www.mountsinai.org/</a> or find Mount Sinai on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">Facebook</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/mountsinainyc/?hl=en">Instagram</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/mountsinainyc/">LinkedIn</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://twitter.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">X</a>, and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/mountsinainy">YouTube</a>.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260310761343/en/">https://www.businesswire.com/news/home/20260310761343/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 10, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

HeartBeam and Mount Sinai partner to develop AI-ECG algorithms for remote heart attack assessment.

<ul><li>Marks HeartBeam’s transition to commercial company</li><li>Rapidly growing practice and highly engaged member population to enable broad adoption</li><li>Enables efficient scaling of additional preventive cardiology and executive health programs</li><li>Establishes initial foothold in structured direct pay healthcare segment representing 5 million patients</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://clearcardio.com/">ClearCardio™</a>, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In addition to serving as HeartBeam’s first commercial customer, ClearCardio also plans to make an investment in HeartBeam, reflecting strong strategic alignment.The partnership includes an initial staged rollout to ensure a seamless patient and physician experience, and plans for broader expansion to thousands of highly engaged members across multiple U.S. geographies. ClearCardio offers its members a cardiac prevention program to monitor cardiac risk factors and will incorporate HeartBeam’s synthesized 12-lead ECG technology into the program for arrhythmia assessment.HeartBeam’s patented cable-free 3D ECG technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG. This allows patients to obtain a high-fidelity, clinical-grade ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind.“ClearCardio was founded on the belief that proactive care, including earlier detection and continuous vigilance, can meaningfully change patient outcomes,” said John Osborne, MD, PhD, Chief Medical Officer of ClearCardio, “HeartBeam’s synthesized 12-lead ECG technology for arrhythmia assessments fits directly into that mission by giving our patients an unprecedented ability to capture meaningful cardiac data whenever symptoms occur while being connected directly to our physicians. This is a major step forward in preventive cardiology.”This collaboration highlights HeartBeam’s fit within a premium, innovation-first segment where patient engagement is high, new product adoption moves quickly, and physicians seek differentiated solutions for patients who are willing to pay for proactive peace of mind. The agreement positions HeartBeam to replicate this model across additional concierge care networks, preventive cardiology groups, and executive health programs nationwide. Additionally, this collaboration supports the validation of HeartBeam’s pricing and subscription-based business model.“ClearCardio becoming our first commercial customer sends a clear message to the market. We believe HeartBeam’s technology is ready, the need is real, and the demand is building,” stated Robert Eno, Chief Executive Officer at HeartBeam. “We believe this is the beginning of a new growth phase for HeartBeam and the first of many milestones to come across our key growth initiatives.”The initial agreement with ClearCardio is structured as a Letter of Intent (LOI), outlining the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase, HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.This commercial milestone aligns directly with HeartBeam’s long-term growth strategy, which includes the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, future indication for heart attack assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About ClearCardioClearCardio, LLC is a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. At the forefront of cardiovascular innovation, ClearCardio specializes in early detection and precision treatment of arterial plaque—the root cause of heart attacks—using cutting-edge AI-powered imaging and non-invasive diagnostics. Working with high-performing professionals, executives, and public safety leaders who know their health impacts more than just themselves, ClearCardio physicians help members detect cardiac disease early, quantify personal risk with clarity and treat the root cause, not just the symptoms. Visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.clearcardio.com/">www.clearcardio.com</a> for more information.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260304586980/en/">https://www.businesswire.com/news/home/20260304586980/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 4, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market

HeartBeam partners with ClearCardio to commercialize its 3D ECG tech for preventive cardiac care.